Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.83 |
| ▸ | CCR1 | P32246 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.50 |
| ▸ | CCR3 | P51677 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805759 | 0.94 | ABCB11 (0.74) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3809421 | 0.94 | ABCB11 (0.79) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL1683017 | 0.93 | ABCB11 (0.83) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813518 | 0.91 | ABCB11 (1.00) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3807855 | 0.91 | ABCB11 (0.75) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3676233 | 0.90 | ABCB11 (0.75) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3676228 | 0.90 | ABCB11 (0.75) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3809444 | 0.89 | ABCB11 (0.72) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL14093760 | 0.89 | ABCB11 (0.79) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3805993 | 0.89 | ABCB11 (0.79) | ABCB11CCR1LMNAHRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| JP-4022142-B2 | — | — | 2007-12-12 | — | — | JP | claimed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | claimed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | claimed |
| JP-2004507461-A | — | — | 2004-03-11 | — | — | JP | claimed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | claimed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | claimed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | claimed |
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7528156-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | disclosed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | disclosed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1299357-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2001098273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | ABCB11 113/4885CCR1 573/4885LMNA 2445/4885 |
| US-20050090494-A1 | Novel compounds | CHRM2, CHRM1, C1R | ABCB11 113/4885CCR1 573/4885LMNA 2445/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | ABCB11 96/4885CCR1 505/4885LMNA 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.